Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus

Nick Freemantlea Institute of Clinical Trials and Methodology, University College London, London, UKCorrespondence[email protected]

https://orcid.org/0000-0001-5807-5740

Didac Mauriciob Department of Endocrinology & Nutrition, Hospital de la Santa Creu i Sant Pau, CIBERDEM, Barcelona, Spain

Andrea Giaccaric Center for Endocrine and Metabolic Diseases, Fondazione Policlinico Universitario A. Gemelli IRCSS, Università Cattolica del Sacro Cuore, Rome, Italy

Timothy Baileyd AMCR Institute, Escondido, CA, USA

Ronan Roussele Department of Diabetology, Endocrinology, and Nutrition, Bichat Hospital, AP-HP, Paris, France;f INSERM U1138, Centre de Recherche des Cordeliers, Paris, France;g UFR de Médecine, Paris University, Paris, France

Denise Francoh CPCLIN Clinical Research Center, São Paulo, Brazil

Baptiste Berthoui IT&M Stats, Paris, France

Valerie Pilorgetj Sanofi, Chilly-Mazarin, France

Jukka Westerbackak Sanofi, Paris, France

Zsolt Bosnyakk Sanofi, Paris, France

Mireille Bonnemairek Sanofi, Paris, France

Anna M. G. Calik Sanofi, Paris, France

My-Liên Nguyên-Pascalj Sanofi, Chilly-Mazarin, France

Alfred Penfornisl Department of Diabetes, Sud-Francilien Hospital, Corbeil-Essonnes and Université Paris Sud, Paris, France

Manuel Perez-Maraverm Servei d´Endocrinologia i Nutrició, Hospital Universitari Bellvitge, L’Hospitalet de Llobregat, IDIBELL, Barcelona, Spain

Jochen Seufertn Faculty of Medicine, Division of Endocrinology and Diabetology, Department of Medicine II, University Hospital of Freiburg, University of Freiburg, Freiburg, Germany

Sean D. Sullivano The CHOICE Institute, School of Pharmacy, University of Washington, Seattle, WA, USA

John Wildingp Obesity and Endocrinology Clinical Research, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, UK

Carol Wyshamq Diabetes and Endocrinology Center, Multicare Rockwood Clinic, Spokane, WA, USA

Melanie Daviesr Diabetes Research Centre, Leicester General Hospital, University of Leicester, Leicester, UK

show all

Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus

Reprints and Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date